Nieves Martinez Lago MD PhD· @DraMartinezLago · X·· 2 天前评分90
正文 · 原文
#ESMO26 🚀 RASolute 302 | Phase III
👥 500 pts | Previously treated mPDAC
💊 Daraxonrasib (RAS(ON) inhibitor) vs chemo
📈 OS: 13.2 vs 6.7 mo (HR 0.40)
🧬 OS benefit by RAS genotype:
🔹 G12D: HR 0.49
🔹 G12V: HR 0.32
🔹 G12R: HR 0.61
📊 PFS: HR 0.55 (BICR)
🎯 ORR: 32% vs 11%
💡 new SOC!
@OncoAlert
2462 浏览 · 39 赞 · 21 转发 · 1 回复
会议摘要
LBA82按 Proffered paper 1: Gastrointestinal tumour, upper digestive 对上
Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Additional subgroup analyses from the ph3 RASolute 302 study
https://esmocongress.esmo.org帖内回复
- Mohit Kasibhatla@MohitKasibhatla
@DraMartinezLago @OncoAlert @myESMO @GrupoTTD How does 20% better RR than chemo with only 1/3 of pts responding yield a doubling in mOS? Isn’t that an outsized benefit?
来源：Nieves Martinez Lago MD PhD · x.com